|
1
|
Zhai YL, Nikaido T, Toki T, Shiozawa A,
Orii A and Fujii S: Prognostic significance of bcl-2 expression in
leiomyosarcoma of the uterus. Br J Cancer. 80:1658–1664. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kotsopoulos IC, Barbetakis N, Asteriou C
and Voutsas MG: Uterine smooth muscle tumor of uncertain malignant
potential: A rare cause of multiple pulmonary nodules. Indian J Med
Paediatr Oncol. 33:176–178. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ip PP, Cheung AN and Clement PB: Uterine
smooth muscle tumors of uncertain malignant potential (STUMP): A
clinicopathologic analysis of 16 cases. Am J Surg Pathol.
33:992–1005. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hewedi IH, Radwan NA and Shash LS:
Diagnostic value of progesterone receptor and p53 expression in
uterine smooth muscle tumors. Diagn Pathol. 7:12012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Copland JA, Luxon BA, Ajani L, Maity T,
Campagnaro E, Guo H, LeGrand SN, Tamboli P and Wood CG: Genomic
profiling identifies alterations in TGFβ signaling through loss of
TGFβ receptor expression in human renal cell carcinogenesis and
progression. Oncogene. 22:8053–8062. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dong M, How T, Kirkbride KC, Gordon KJ,
Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR and Blobe GC: The
type III TGF-β receptor suppresses breast cancer progression. J
Clin Invest. 117:206–217. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Turley RS, Finger EC, Hempel N, How T,
Fields TA and Blobe GC: The type III transforming growth factor-β
receptor as a novel tumor suppressor gene in prostate cancer.
Cancer Res. 67:1090–1098. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu XL, Xiao K, Xue B, Yang D, Lei Z, Shan
Y and Zhang HT: Dual role of TGFBR3 in bladder cancer. Oncol Rep.
30:1301–1308. 2013.PubMed/NCBI
|
|
9
|
Luan SL, Boulanger E, Ye H, Chanudet E,
Johnson N, Hamoudi RA, Bacon CM, Liu H, Huang Y, Said J, et al:
Primary effusion lymphoma: Genomic profiling revealed amplification
of SELPLG and CORO1C encoding for proteins important for cell
migration. J Pathol. 222:166–179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mataki H, Enokida H, Chiyomaru T, Mizuno
K, Matsushita R, Goto Y, Nishikawa R, Higashimoto I, Samukawa T,
Nakagawa M, et al: Downregulation of the microRNA-1/133a cluster
enhances cancer cell migration and invasion in lung-squamous cell
carcinoma via regulation of Coronin1C. J Hum Genet. 60:53–61. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Petrini I, Meltzer PS, Zucali PA, Luo J,
Lee C, Santoro A, Lee HS, Killian KJ, Wang Y, Tsokos M, et al: Copy
number aberrations of BCL2 and CDKN2A/B identified by array-CGH in
thymic epithelial tumors. Cell Death Dis. 3:e3512012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Panzeri E, Conconi D, Antolini L, Redaelli
S, Valsecchi MG, Bovo G, Pallotti F, Viganò P, Strada G, Dalprà L,
et al: Chromosomal aberrations in bladder cancer: Fresh versus
formalin fixed paraffin embedded tissue and targeted FISH versus
wide microarray-based CGH analysis. PLoS One. 6:e242372011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Silvestrini R, Veneroni S, Daidone MG,
Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F and Veronesi
U: The Bcl-2 protein: A prognostic indicator strongly related to
p53 protein in lymph node-negative breast cancer patients. J Natl
Cancer Inst. 86:499–504. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alderson LM, Castleberg RL, Harsh GR IV,
Louis DN and Henson JW: Human gliomas with wild-type p53 express
bcl-2. Cancer Res. 55:999–1001. 1995.PubMed/NCBI
|
|
15
|
Fontanini G, Vignati S, Bigini D, Mussi A,
Lucchi M, Angeletti CA, Basolo F and Bevilacqua G: Bcl-2 protein: A
prognostic factor inversely correlated to p53 in non-small-cell
lung cancer. Br J Cancer. 71:1003–1007. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kaklamanis L, Savage A, Whitehouse R,
Doussis-Anagnostopoulou I, Biddolph S, Tsiotos P, Mortensen N,
Gatter KC and Harris AL: Bcl-2 protein expression: Association with
p53 and prognosis in colorectal cancer. Br J Cancer. 77:1864–1869.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yip KW and Reed JC: Bcl-2 family proteins
and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Scarfò L and Ghia P: Reprogramming cell
death: BCL2 family inhibition in hematological malignancies.
Immunol Lett. 155:36–39. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Talaiezadeh A, Jalali F, Galehdari H and
Khodadadi A: Time depended Bcl-2 inhibition might be useful for a
targeted drug therapy. Cancer Cell Int. 15:1052015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fischer H, Stenling R, Rubio C and
Lindblom A: Colorectal carcinogenesis is associated with stromal
expression of COL11A1 and COL5A2. Carcinogenesis. 22:875–878. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang LH, Xiang J, Yan M, Zhang Y, Zhao Y,
Yue CF, Xu J, Zheng FM, Chen JN, Kang Z, et al: The mitotic kinase
Aurora-A induces mammary cell migration and breast cancer
metastasis by activating the Cofilin-F-actin pathway. Cancer Res.
70:9118–9128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stadler ZK, Esposito D, Shah S, Vijai J,
Yamrom B, Levy D, Lee YH, Kendall J, Leotta A, Ronemus M, et al:
Rare de novo germline copy-number variation in testicular cancer.
Am J Hum Genet. 91:379–383. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mudduluru G, Vajkoczy P and Allgayer H:
Myeloid zinc finger 1 induces migration, invasion, and in vivo
metastasis through Axl gene expression in solid cancer. Mol Cancer
Res. 8:159–169. 2010. View Article : Google Scholar : PubMed/NCBI
|
